CREATING COVX-BODIES

CovX-Bodies are created by covalently joining a pharmacophore via proprietary linkers to the binding site of a specially designed antibody; effectively reprogramming the antibody. The result is a new class of chemical entities that is formed where each component contributes desirable traits to the intact CovX-Body. We have successfully demonstrated the utility of our technology by enhancing the pharmacokinetic and pharmacodynamic profiles of peptides and small molecules across several disease areas.

Step 1 A programming agent (comprised of a peptide incorporating a specific CovX linker) is synthesized. The linker is designed to be recognized and covalently bound only by the active binding site of the antibody.		Step 2 In a well-controlled reaction, a programming agent is combined with CovX’s unique antibody.		Step 3 The result is a well-characterized, bivalent CovX-Body that possesses the biologic actions of the peptide and the extended half-life of the antibody.

One Antibody > Multiple Products

Designed for human compatibility, all CovX-Bodies incorporate the same antibody.  The unique interaction of the CovX antibody and tethers allows the creation of multiple CovX-Bodies using a single “scaffold.”  This approach provides rapid development, reduced costs, and a defined regulatory path. 

CovX’s technology provides tunable and predictable increases to a peptide’s half-life.  Furthermore, CovX-Bodies enhance a peptides therapeutic potential beyond extending half-lives; CovX-Bodies exhibit true bivalency which enhances potency and block protein-protein interactions.